Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:27:00.874Z.
Calculation as of: 2026-10-06T15:27:00.874Z.
Quote observation: 2026-10-06T15:25:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e02887d9f7d553dead588493e3d1cc1cda6164751857f77264c258b40fe63259
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$287.26M
EBITDA Yield
N/A
TTM Avg
6.11%
3Y Avg
6.11%
5Y Avg
6.11%
Market Cap
$278.12M
EBITDA Yield
N/A
TTM Avg
12.31%
3Y Avg
12.19%
5Y Avg
12.19%
Market Cap
$295.60M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$273.56M
EBITDA Yield
N/A
TTM Avg
10.04%
3Y Avg
10.04%
5Y Avg
9.67%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | $283.44M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $282.54M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $287.26M | N/A | 6.11% | 6.11% | 6.11% |
| Aurora Cannabis Inc. (ACB)vs › | $278.12M | N/A | 12.31% | 12.19% | 12.19% |
| Fate Therapeutics, Inc. (FATE)vs › | $278.58M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $293.66M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $295.60M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $292.50M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $273.56M | N/A | 10.04% | 10.04% | 9.67% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $267.84M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
